论文部分内容阅读
The aim is to evaluate the effect of ciprofloxacin and chloramphenicol on anti-BSA antibody production triggered by bovine albumin encapsulated in non-ionic surfactant vesicle,niosomes.Reverse phase evaporation method was adopted to entrap the antigen in colloidal carrier composed of Span 80 and Span 85 followed by simultaneous characterization for particle size,entrapment efficiency and in vitro release.The protein content was determined by Bradford method using UV Visible Spectrophotometer at 595 nm.Humoral immune response was measured in terms of systemic IgG antibody titre by ELISA method.Experimental data indicated that 7∶3 molar ratio of Span 80 and cholesterol based niosomal formulation possessed maximum(39.8±2.9)% of soluble protein.Ciprofloxacin markedly(P<0.05) decreased the antibody titre.In contrast,chloramphenicol did not reduce the antibody titre significantly in comparison to control group(P>0.05).It is necessary to explore the effect of a vaccine antigen when a candidate is medicated with a therapeutic agent,which might help in programming a new drug management and vaccination programme.
The aim is to evaluate the effect of ciprofloxacin and chloramphenicol on anti-BSA antibody production triggered by bovine albumin encapsulated in non-ionic surfactant vesicles, niosomes. Reverse phase evaporation method was adopted to entrap the antigen in colloidal carrier composed of Span 80 and Span 85 followed by simultaneous characterization for particle size, entrapment efficiency and in vitro release. The protein content was determined by Bradford method using UV Visible Spectrophotometer at 595 nm. Humoral immune response was measured in terms of systemic IgG antibody titre by ELISA method. Experimental data indicated that 7:3 molar ratio of Span 80 and cholesterol based niosomal formulation possessed maximum (39.8 ± 2.9)% of soluble protein. Ciprofloxacin markedly (P <0.05) decreased the antibody titre. In contrast, chloramphenicol did not reduce the antibody titre in comparison to control group (P> 0.05). It is necessary to explore the effect of a vaccine antigen when a candi date is medicated with a therapeutic agent, which might help in programming a new drug management and vaccination program.